SMARCB1 and neoplasm: That SMARCB1 KD leads to elevated accessibility at CTCF binding sites is particularly noteworthy given recent findings that a SMARCB1-excluding non-canonical SWI/SNF complex (ncBAF, also termed GBAF) preferentially targets CTCF sites in mESCs and several tumor cell lines (Gatchalian et al., 2018; Michel et al., 2018).